InvestorsHub Logo
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

Re: DanWebzster post# 176

Monday, 05/28/2018 5:42:21 AM

Monday, May 28, 2018 5:42:21 AM

Post# of 438
NBRV will file an NDA for lemefulin in CABP in Q4/18

Cash runway thru Q1/20

Public float has been bloated to achieve that cash runway

Despite efficacy proven in two Ph3 studies, recent stock weakness has been attributed to safety concerns

Safety concerns focus on diarrhea found in 12% of treatment arm compared to 1% of control arm.

Lemefulin will mostly be prescribed for drug resistant cases of CABP, approximately 5% of the market

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.